Dexcom G7 CGM Proven Effective in Non-Insulin Type 2 Diabetes: CONNECT Study
Key Questions
What were the results of the CONNECT study for Dexcom G7?
In non-insulin T2D, Dexcom G7 led to 0.9% greater A1C reduction and 5 hours more time in range vs blood glucose monitoring. Benefits were consistent across groups.
Is CGM now recommended for non-insulin treated type 2 diabetes?
The level A evidence from CONNECT could shift standard of care to expand CGM beyond insulin users. It shows clear benefits in glycemic control.
Has the FDA approved over-the-counter CGMs for children?
The FDA cleared Dexcom's Stelo as the first OTC continuous glucose monitor for children. This expands access alongside professional uses in diabetes management.
The CONNECT study presented at ADA 2026 shows Dexcom G7 continuous glucose monitoring in non-insulin-treated T2D patients leads to 0.9% greater A1C reduction vs self-monitoring blood glucose, with 5 hours more time in range per day. Benefits were consistent across demographics and medication classes. This level A evidence could shift standard of care, expanding CGM use beyond insulin users.